Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurogene (NGNE) PT Lowered to $45 at BMO Capital
November 19, 2024 4:02 PM ESTBMO Capital analyst Keith Tapper lowered the price target on Neurogene (NASDAQ: NGNE) to $45.00 (from $60.00) while maintaining a Outperform rating.
The analyst comments "Neurogene shares are trading near cash on: 1) emerging SAE in a high-dose patient, consistent with overexposure/overdose of AAV9 or adenovirus... More
